Parke-Davis Signs Deal to Use Genzyme Division's Technology | GenomeWeb

FRAMINGHAM, Mass.--Genzyme Molecular Oncology here could earn more than $9 million from a new service and option-to-license agreement it has signed that allows Parke-Davis to use the company's proprietary Sage technology in gene expression studies. Parke-Davis may choose to license Sage for its internal genomics research programs. Initially, the technology will be used in a pharmacogenomics study to analyze gene expression changes in tissue following exposure to potential new drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.